Drug Type Mesenchymal stem cell therapy |
Synonyms Allo-hMSCs |
Target- |
Action- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggression | Phase 2 | United States | 01 May 2025 | |
Agitation in Dementia | Phase 2 | United States | 01 May 2025 | |
Alzheimer Disease | Phase 2 | United States | 01 May 2025 | |
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 2 | United States | 16 Aug 2021 | |
Endothelial dysfunction | Phase 2 | United States | 16 Aug 2021 | |
Cardiomyopathy, Dilated | Phase 2 | United States | 07 May 2021 | |
Non-ischemic Cardiomyopathy | Phase 2 | United States | 07 May 2021 | |
Back Pain | Phase 2 | United States | 01 Dec 2020 | |
Myocardial Infarction | Phase 2 | United States | 13 Feb 2014 | |
Ventricular Dysfunction, Left | Phase 2 | United States | 13 Feb 2014 |
Phase 1/2 | 16 | (Pilot Phase 20 Million Allogeneic hMSCs) | kfeynpwpup = pcfpicbcgg wjjhamwilq (ihuyogkpcn, toeydtkbrv - gabayiignh) View more | - | 11 May 2022 | ||
(Pilot Phase 100 Million hMSCs) | kfeynpwpup = tphjcbieva wjjhamwilq (ihuyogkpcn, yzkuxmfjtc - jducmqritr) View more | ||||||
Phase 2 | 30 | (Group 1: 20 Million Allogeneic hMSCs) | enqmbuouux = unbxfrniya cdpaiatlow (xvzokfsqzj, gteeoirwwv - aydhbjegpi) View more | - | 05 Feb 2020 | ||
(Group 2: 100 Million Allogeneic hMSCs) | enqmbuouux = upxrtnxvjs cdpaiatlow (xvzokfsqzj, aqlwlwcpxn - rfnlrmuhdo) View more | ||||||
Phase 1/2 | 37 | (Autologous hMSCs) | ibxxdzingu = csxiwtfsux shwsjaibom (sfkyuxsvak, jmsooyqwdc - neuererchq) View more | - | 15 Feb 2018 | ||
(Allogeneic hMSCs) | ibxxdzingu = sllszkkyxm shwsjaibom (sfkyuxsvak, ultfhpyenn - pxvnjymyha) View more |